Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC, van Dijk B, de Joode K, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Jalving M, de Jonge MJA, Joosse A, Kapiteijn E, Kamphuis-Huismans AM, Naipal KAT, Piersma D, Rikhof B, Westgeest HM, Vreugdenhil G, Oomen-de Hoop E, Mulder EEAP, van der Veldt AAM. Janssen JC, et al. Among authors: joosse a. BMC Cancer. 2024 May 23;24(1):632. doi: 10.1186/s12885-024-12336-0. BMC Cancer. 2024. PMID: 38783238 Free PMC article.
Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
van der Kooij MK, Joosse A, Speetjens FM, Hospers GA, Bisschop C, de Groot JW, Koornstra R, Blank CU, Kapiteijn E. van der Kooij MK, et al. Among authors: joosse a. Acta Oncol. 2017 Jan;56(1):101-103. doi: 10.1080/0284186X.2016.1260773. Epub 2016 Dec 2. Acta Oncol. 2017. PMID: 27911126 No abstract available.
Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
Hurkmans DP, Verhoeven JGHP, de Leur K, Boer K, Joosse A, Baan CC, von der Thüsen JH, van Schaik RHN, Mathijssen RHJ, van der Veldt AAM, Hesselink DA. Hurkmans DP, et al. Among authors: joosse a. J Immunother Cancer. 2019 Jul 12;7(1):182. doi: 10.1186/s40425-019-0653-6. J Immunother Cancer. 2019. PMID: 31300068 Free PMC article.
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
Basak EA, Vermeer NS, de Joode K, Hurkmans DP, Velthuis DEM, Oomen-de Hoop E, Schreurs MWJ, Bins S, Koolen SLW, Debets R, van der Veldt AAM, Aerts JGJV, Joosse A, Mathijssen RHJ. Basak EA, et al. Among authors: joosse a. Eur J Cancer. 2022 Oct;174:113-120. doi: 10.1016/j.ejca.2022.07.015. Epub 2022 Aug 19. Eur J Cancer. 2022. PMID: 35988409 Free article.
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
Basak EA, de Joode K, Uyl TJJ, van der Wal R, Schreurs MWJ, van den Berg SAA, Oomen-de Hoop E, van der Leest CH, Chaker L, Feelders RA, van der Veldt AAM, Joosse A, Koolen SLW, Aerts JGJV, Mathijssen RHJ, Bins S. Basak EA, et al. Among authors: joosse a. Biomed Pharmacother. 2022 Dec;156:113839. doi: 10.1016/j.biopha.2022.113839. Epub 2022 Oct 11. Biomed Pharmacother. 2022. PMID: 36228374 Free article.
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
van der Kooij MK, Joosse A, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, Dekkers OM, Kapiteijn E. van der Kooij MK, et al. Among authors: joosse a. Br J Cancer. 2023 Mar;128(5):707-710. doi: 10.1038/s41416-022-02088-8. Epub 2022 Dec 23. Br J Cancer. 2023. PMID: 36564561 Free PMC article. No abstract available.
30 results